Document Detail


Anti-tumor activity of dehydroxymethylepoxyquinomicin against human oral squamous cell carcinoma cell lines in vitro and in vivo.
MedLine Citation:
PMID:  21459660     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Several reports have indicated that nuclear factor-kappa B (NF-κB) is constitutively activated in a variety of cancer cells including human oral squamous carcinoma cells, and play a key role in their growth and survival. Recent studies report that NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), inhibits proliferation and induces apoptosis in prostate cancer cell lines. However this anti-tumor effects are still unknown in end human oral squamous carcinoma cells. In the present study, we investigated the effects of DHMEQ on oral squamous carcinoma cell (OSCC) lines in vitro and in vivo. Human OSCC cell lines (HSC-3, SAS) were treated with DHMEQ and examined for cell viability by MTT assay, cell cycle distribution by flow-cytometry, apoptosis by TUNEL assay, and protein expression by western blotting, respectively. In vivo activities were also investigated in a mouse xenograft model. DHMEQ inhibited growth of two OSCC cell lines in a dose-dependent manner measured by MTT assay. A flow cytometric analysis demonstrated that treatment with DHMEQ induced accumulation in sub-G1 phase. TUNEL assay showed that DHMEQ induced DNA fragmentation. Protein expression by western blotting analysis revealed that DHMEQ induced nuclear down regulation of Survivin, cIAP-1, and cIAP-2. In nude mice, DHMEQ inhibited growth of OSCC without major toxic side effects. The present results demonstrated that administration of DHMEQ is suggested to be a novel anti-tumor approach to the treatment of OSCC.
Authors:
Arisa Yasuda; Seiji Kondo; Tatsuhito Nagumo; Hikari Tsukamoto; Yoshiki Mukudai; Kazuo Umezawa; Satoru Shintani
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2011-04-02
Journal Detail:
Title:  Oral oncology     Volume:  47     ISSN:  1879-0593     ISO Abbreviation:  Oral Oncol.     Publication Date:  2011 May 
Date Detail:
Created Date:  2011-05-20     Completed Date:  2011-08-24     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  9709118     Medline TA:  Oral Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  334-9     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Elsevier Ltd. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antineoplastic Agents / pharmacology*
Benzamides / pharmacology*
Carcinoma, Squamous Cell / drug therapy*,  mortality
Cell Cycle / drug effects*,  genetics
Cell Line, Tumor
Cyclohexanones / pharmacology*
Dose-Response Relationship, Drug
Flow Cytometry
Humans
Inhibitor of Apoptosis Proteins / metabolism
Mice
Mouth Neoplasms / drug therapy*,  pathology
NF-kappa B / antagonists & inhibitors*,  metabolism
Reverse Transcriptase Polymerase Chain Reaction
Tumor Cells, Cultured
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Benzamides; 0/Cyclohexanones; 0/Inhibitor of Apoptosis Proteins; 0/NF-kappa B; 0/dehydroxymethylepoxyquinomicin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Role of chemoradiotherapy in intermediate prognosis nasopharyngeal carcinoma.
Next Document:  A meta-analysis of the randomized controlled trials on elective neck dissection versus therapeutic n...